Business Insight & People News
In Vitro & In Vivo Diagnostic Substances
Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.
Revenue and net income below are for fiscal period FY2025, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.
Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.
Everyone below has filed at least one insider report against this company.
Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.
| Insider | Reported role | Shares | Value | Last action |
|---|---|---|---|---|
| Kenneth F. Buechler | Board Member | 101,921 | $1.42M | A Grant or award Jun 6, 2026 position reported |
| Matthew Strobeck | Board Member | 82,550 | $1.15M | A Grant or award May 29, 2026 position reported |
| Ann D. Rhoads | Board Member | 15,021 | $209.8K | A Grant or award May 29, 2026 position reported |
|
|
Board Member | 10,624 | $148.4K | A Grant or award May 29, 2026 position reported |
| R Scott Huennekens | Board Member | 2,523 | $35.2K | A Grant or award May 29, 2026 position reported |
The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.
A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.
| Date | Insider | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jun 6, 2026 | Kenneth F. Buechler | A Grant or award | 497 | $0.00 | $0 | SEC filing ↗ |
| Jun 6, 2026 | Kenneth F. Buechler | A Grant or award | 1,659 | $0.00 | $0 | SEC filing ↗ |
| May 29, 2026 | Evelyn S Dilsaver | A Grant or award | 6,829 | $0.00 | $0 | SEC filing ↗ |
| May 29, 2026 | Matthew Strobeck | A Grant or award | 6,829 | $0.00 | $0 | SEC filing ↗ |
| May 29, 2026 | R Scott Huennekens | A Grant or award | 6,829 | $0.00 | $0 | SEC filing ↗ |
| May 29, 2026 | Ann D. Rhoads | A Grant or award | 6,829 | $0.00 | $0 | SEC filing ↗ |
| May 29, 2026 | Kenneth F. Buechler | A Grant or award | 6,829 | $0.00 | $0 | SEC filing ↗ |
| May 22, 2026 | Ann D. Rhoads | A Grant or award | 234 | $0.00 | $0 | SEC filing ↗ |
| May 22, 2026 | Ann D. Rhoads | A Grant or award | 1,173 | $0.00 | $0 | SEC filing ↗ |
| Feb 13, 2026 | Matthew Strobeck | P Open-market purchase | 10,000 | $23.96 | $239.6K | SEC filing ↗ |
| Dec 10, 2025 | Ann D. Rhoads | P Open-market purchase | 750 | $28.28 | $21.2K | SEC filing ↗ |
| Jul 15, 2025 | Kenneth F. Buechler | M Option exercise or conversion | 9,215 | $15.74 | $145.0K | SEC filing ↗ |
| May 24, 2025 | Ann D. Rhoads | A Grant or award | 546 | $0.00 | $0 | SEC filing ↗ |
| May 24, 2025 | Ann D. Rhoads | A Grant or award | 109 | $0.00 | $0 | SEC filing ↗ |
| May 24, 2025 | Evelyn S Dilsaver | A Grant or award | 80 | $0.00 | $0 | SEC filing ↗ |
| May 24, 2025 | Evelyn S Dilsaver | A Grant or award | 402 | $0.00 | $0 | SEC filing ↗ |
| May 22, 2025 | R Scott Huennekens | A Grant or award | 2,523 | $0.00 | $0 | SEC filing ↗ |
| May 22, 2025 | Ann D. Rhoads | A Grant or award | 4,929 | $0.00 | $0 | SEC filing ↗ |
| May 22, 2025 | Kenneth F. Buechler | A Grant or award | 4,929 | $0.00 | $0 | SEC filing ↗ |
| May 22, 2025 | Matthew Strobeck | A Grant or award | 4,929 | $0.00 | $0 | SEC filing ↗ |
| May 22, 2025 | Evelyn S Dilsaver | A Grant or award | 4,929 | $0.00 | $0 | SEC filing ↗ |
| May 18, 2025 | Ann D. Rhoads | A Grant or award | 128 | $0.00 | $0 | SEC filing ↗ |
| May 18, 2025 | Ann D. Rhoads | A Grant or award | 427 | $0.00 | $0 | SEC filing ↗ |
| May 18, 2025 | Kenneth F. Buechler | A Grant or award | 236 | $0.00 | $0 | SEC filing ↗ |
| May 18, 2025 | Kenneth F. Buechler | A Grant or award | 789 | $0.00 | $0 | SEC filing ↗ |
From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.
The report an officer, director or large shareholder must file after trading their own company’s stock.
Funds, trusts and other companies file the same ownership forms that executives do. Everything below is taken from those filings, with the position exactly as the filing states it.
Do not add these figures together. 9 of the positions below were reported on filings shared by several filers at once.
On a joint filing every named filer is listed against the whole position, so the same block of stock appears under each name. Those rows are marked joint.
| Owner | Reported role | Shares | Filed |
|---|---|---|---|
| Carlyle Group Inc. CG | TenPercentOwner | 0 joint | |
| Carlyle Holdings II GP L.L.C. | TenPercentOwner | 0 joint | |
| Carlyle Holdings II L.L.C. | TenPercentOwner | 0 joint | |
| Carlyle Partners VI Cayman Holdings, L.P. | TenPercentOwner | 0 joint | |
| CG Subsidiary Holdings L.L.C. | TenPercentOwner | 0 joint | |
| TC Group Cayman Investment Holdings Sub L.P. | TenPercentOwner | 0 joint | |
| TC Group Cayman Investment Holdings, L.P. | Other,TenPercentOwner | 0 joint | |
| TC Group VI Cayman, L.L.C. | TenPercentOwner | 0 joint | |
| TC Group VI Cayman, L.P. | TenPercentOwner | 0 joint |
See the full ownership map — every entity that files as an owner of a US public company.
67 legal entities named in the subsidiary exhibit filed with this company’s most recent 10-K. . Filing on SEC.gov.
This is not the full list. SEC rules only require a company to name its significant subsidiaries.
Smaller entities are left out of the exhibit entirely. A short list here means a short exhibit — it does not mean the company owns nothing else. Nothing on this page is inferred: every name below is copied from the filing.
| Subsidiary | Organised in |
|---|---|
| BioHelix Corporation | Massachusetts, United States |
| Branch of Ortho-Clinical Diagnostics Netherlands B.V. | Saudi Arabia |
| Crimson Germany GmbH | Germany |
| Crimson International Assets LLC | Delaware, United States |
| Crimson OCD (UK) Limited | United Kingdom |
| Diagnostic Hybrids, Inc. | Ohio, United States |
| Germany OCD Co GmbH | Germany |
| Germany OCD Holding GmbH & Co. KG | Germany |
| Immutopics, Inc. | California, United States |
| Micro Typing Systems, Inc. | Florida, United States |
| OCD Clinical Diagnostics Portugal, Unipessoal Lda | Portugal |
| OCD Investment Holdings B.V. | Netherlands |
| Orca Holdco 2, Inc. | Delaware, United States |
| Orca Holdco, Inc. | Delaware, United States |
| Ortho Clinical Diagnostics Biotechnology Development Shanghai Co. Ltd. | China |
| Ortho Clinical Diagnostics Do Brasil Produtos Para Saude Ltda. | Brazil |
| Ortho Clinical Diagnostics India Private Limited | India |
| Ortho-Clinical Diagnostics | United Kingdom |
| Ortho-Clinical Diagnostics (Thailand) Ltd. | Thailand |
| Ortho-Clinical Diagnostics Australia Pty Ltd. | Australia |
| Ortho-Clinical Diagnostics Chile SpA | Chile |
| Ortho-Clinical Diagnostics Colombia SAS | Colombia |
| Ortho-Clinical Diagnostics Czech s.r.o. | Czech Republic |
| Ortho-Clinical Diagnostics Denmark, filial af Ortho-Clinical Diagnostics Netherlands B.V. | Denmark |
| Ortho-Clinical Diagnostics Egypt for Trading & Importation LLC | Egypt |
| Ortho-Clinical Diagnostics Egypt Investment LLC | Egypt |
| Ortho-Clinical Diagnostics Egypt Services LLC | Egypt |
| Ortho-Clinical Diagnostics FinCo S.à r.l. | Barbados |
| Ortho-Clinical Diagnostics France SAS | France |
| Ortho-Clinical Diagnostics GmbH | Austria |
| Ortho-Clinical Diagnostics Holdings Luxembourg S.à r.l. | Luxembourg |
| Ortho-Clinical Diagnostics Italy S.r.l. | Italy |
| Ortho-Clinical Diagnostics K.K. | Japan |
| Ortho-Clinical Diagnostics Limited Liability Company | Russia |
| Ortho-Clinical Diagnostics Luxembourg S.à r.l. | Luxembourg |
| Ortho-Clinical Diagnostics MEA | Dubai |
| Ortho-Clinical Diagnostics Medical Technology (Changsha) Co., Ltd. | China |
| Ortho-Clinical Diagnostics Mexico Operations S. de R.L. de C.V. | Mexico |
| Ortho-Clinical Diagnostics Mexico Services S. de R.L. de C.V. | Mexico |
| Ortho-Clinical Diagnostics Netherlands B.V. | Netherlands |
| Ortho-Clinical Diagnostics Norway (branch of Ortho-Clinical Diagnostics Netherlands B.V.) | Norway |
| Ortho-Clinical Diagnostics NV | Belgium |
| Ortho-Clinical Diagnostics Panama Export S.A. | Panama |
| Ortho-Clinical Diagnostics Panama S.A. | Panama |
| Ortho-Clinical Diagnostics Philippines Inc. | Philippines |
| Ortho-Clinical Diagnostics S.à r.l. | Luxembourg |
| Ortho-Clinical Diagnostics Singapore Pte. Ltd. | Singapore |
| Ortho-Clinical Diagnostics Spain, S.L. | Spain |
| Ortho-Clinical Diagnostics Sweden AB | Sweden |
| Ortho-Clinical Diagnostics Switzerland GmbH | Switzerland |
| Ortho-Clinical Diagnostics Trading (China) Co. Ltd. | China |
| Ortho-Clinical Diagnostics U.S. FinanceCo I, LLC | Delaware, United States |
| Ortho-Clinical Diagnostics, Inc. | New York, United States |
| Quidel Cardiovascular Inc. | Delaware, United States |
| Quidel Corporation | Delaware, United States |
| Quidel Diagnostics India Private Limited | India |
| Quidel France SARL | France |
| Quidel Germany, GmbH | Germany |
| Quidel Hong Kong, Ltd. | Hong Kong |
| Quidel International, LLC | Delaware, United States |
| Quidel Ireland Limited | Ireland |
| Quidel Italy SRL | Italy |
| Quidel Services, LLC | Delaware, United States |
| QuidelOrtho Canada Corporation | Canada |
| QuidelOrtho Health Operational Services Limited Company | Turkey |
| QuidelOrtho Regional Headquarters Company | Saudi Arabia |
| QuidelOrtho Sales Company, LLC | Delaware, United States |
A subsidiary is a separate legal entity this company controls; it is not the same thing as a brand, a division or an office. These entities do not file with the SEC in their own right, so there is no separate page to open for them.
Think a number here is wrong? Open the linked filing and compare — how to report it.
Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.
Share count: cover page of the latest filing (dei:EntityCommonStockSharesOutstanding), taken from
QuidelOrtho Corp’s own filings and multiplied by our closing price.
Full method.
the share count the company itself prints on the cover of its most recent filing, as of the date it signed that filing.
We do not take a market cap from a data vendor, and we do not estimate one: the figure is a share count from QuidelOrtho Corp’s own SEC filings multiplied by the closing price we hold for the same stock.